More About Becky
Becky Pferdehirt, PhD, is an investing partner on the Bio + Health team. She focuses on early stage companies building technology platforms for therapeutic discovery and development. She is involved in companies like: Cartography Bio, Vicinitas Therapeutics, Scribe Therapeutics, BioAge Labs, Genesis Therapeutics, Inceptive, GC Therapeutics, Trotana, Patch Bio, Stipple Bio, and Siduma Therapeutics.
Prior to joining Andreessen Horowitz, Becky worked at Amgen, where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD, Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation.
Becky completed her postdoctoral education at Genentech, studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT. She grew up in the midwest across Chicago and Madison, and in her free time enjoys spending time with her two daughters, skiing and kiteboarding.
Latest Content
-
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
-
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations.
-
a16z Bio + Health investment partner Becky Pferdehirt chats with Robbie Majzner, MD, an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford, and co-founder of Link Cell Therapies.
-
Biotech founders face a variety of challenges in building a successful startup. Beyond confronting daunting scientific and technical hurdles, they must develop a strategy to ensure their technology has a compelling business model and is focused on the right problems. Also, they need a plan for how the tech will go the distance — i.e., when to go it alone or seek to partner.
